Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
19.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 108 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
19.03. | Sera Prognostics appoints Jeff Elliott to board | 1 | Investing.com | ||
19.03. | SERA PROGNOSTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
19.03. | Sera Prognostics GAAP EPS of -$0.25 misses by $0.01, revenue of $0.02M | 4 | Seeking Alpha | ||
19.03. | SERA PROGNOSTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
19.03. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
18.03. | Sera Prognostics A: Finanzielle Herausforderungen und Zukunftsaussichten | 1 | IT BOLTWISE | ||
11.02. | Sera Prognostics dips 5%, prices $50M offering | 2 | Seeking Alpha | ||
10.02. | Sera Prognostics announces proposed public offering | 2 | Seeking Alpha | ||
10.02. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
31.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
07.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 87 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
06.11.24 | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
06.11.24 | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
07.08.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2024 Financial Results | 123 | PR Newswire | SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen | |
08.05.24 | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2024 Financial Results | 233 | PR Newswire | SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NANOREPRO | 1,305 | -2,61 % | EQS-News: NanoRepro AG: NanoRepro erhält EU-Qualitätsmanagementbescheinigung nach Verordnung (EU) 2017/746 für In-vitro-Diagnostika | EQS-News: NanoRepro AG
/ Schlagwort(e): Sonstiges
NanoRepro AG: NanoRepro erhält EU-Qualitätsmanagementbescheinigung nach Verordnung (EU) 2017/746 für In-vitro-Diagnostika
16.04.2025... ► Artikel lesen | |
OCUGEN | 0,646 | +2,02 % | Ocugen Aktie: Leichte Erholung nach schwierigem Jahr | Trotz langfristiger Verluste halten Analysten an positiven Bewertungen für Ocugen fest. Die Gentherapie-Pipeline bleibt der zentrale Hoffnungsträger. Die Ocugen-Aktie zeigt heute eine leichte Erholung... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,130 | -2,83 % | Viking Therapeutics Aktie: Wichtige Trends beobachtet | Biotech-Aktie mit starkem Jahresminus, doch Experten sehen hohes Potenzial. Entscheidende Quartalszahlen stehen bevor. Die Viking Therapeutics-Aktie zeigt sich zum Wochenstart mit leichten Gewinnen:... ► Artikel lesen | |
COSCIENS BIOPHARMA | 2,520 | 0,00 % | COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer | 25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO... ► Artikel lesen | |
SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal | San Antonio, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,084 | +0,88 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2025 Financial Results on May 5 | ||
VAXART | 0,312 | +2,64 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
REDHILL BIOPHARMA | 2,300 | +2,22 % | RedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency | The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected... ► Artikel lesen | |
IBIO | 0,745 | 0,00 % | iBio, Inc. - 8-K, Current Report | ||
ARBUTUS BIOPHARMA | 2,840 | -0,56 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
ALDEYRA | 2,135 | +0,09 % | Aldeyra Therapeutics, Inc. - 8-K, Current Report | ||
MANNKIND | 4,089 | +0,57 % | MannKind Corp. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for MannKind Corp. (MNKD):Earnings: $7.42 million in Q4 vs. $1.40 million in the same period last year.
EPS: $0.03 in Q4 vs. $0.00... ► Artikel lesen | |
CARDIFF ONCOLOGY | 2,560 | -0,97 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of... ► Artikel lesen | |
TRAWS PHARMA | 1,760 | -100,00 % | Traws Pharma, Inc. - 8-K, Current Report | ||
CARISMA THERAPEUTICS INC | 0,185 | -3,75 % | Carisma Therapeutics Inc.: Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline | Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies
Development of CT-0525... ► Artikel lesen |